title: Induction of C3 expression in astrocytes is regulated by cytokines and Newcastle disease virus.
abstract: Synthesis of complement proteins and their regulation in resident cells of the central nervous system are important pathophysiologic factors that can affect the outcome of inflammatory central nervous system diseases. Primary cultures of rat astrocytes constitutively express C3 mRNA and produce C3 protein; both of them were enhanced by LPS or by a live as well as inactivated Newcastle disease virus, a neurotropic paramixovirus. TNF, IL-1 beta, and IL-8 also increased the levels of C3 mRNA and protein whereas IL-1 alpha and IL-6 had no effect, although all of these cytokines are inducible by LPS. LPS stimulation in the presence of cycloheximide decreased the LPS-mediated C3 mRNA induction by 60%. These data suggest that LPS effect on C3 regulation is mediated directly by LPS as well as by LPS-induced cytokines. Interestingly, C3 mRNA induced by Newcastle disease virus or inactivated Newcastle disease virus was inhibited by protein kinase inhibitors, H-7 and staurosporine, whereas these inhibitors had no effect on C3 induction mediated by LPS or cytokines, indicating the existence of different signal transduction pathways.
authors.affiliation: Department of Pathology, University of Maryland, School of Medicine, Baltimore 21201.
authors.forename: H G
authors.initials: HG
authors.lastname: Rus
authors.forename: L M
authors.initials: LM
authors.lastname: Kim
authors.forename: F I
authors.initials: FI
authors.lastname: Niculescu
authors.forename: M L
authors.initials: ML
authors.lastname: Shin
mesh_terms: D000470:Alkaloids / Q000494:pharmacology; D000818:Animals; D001253:Astrocytes / Q000502:physiology*; D002352:Carrier Proteins / Q000235:genetics; D003176:Complement C3 / Q000235:genetics*; D003180:Complement C3b Inactivator Proteins / Q000235:genetics; D003181:Complement C4 / Q000235:genetics; D017242:Complement Factor H; D016207:Cytokines / Q000494:pharmacology*; D015870:Gene Expression / Q000187:drug effects; D016167:Integrin alphaXbeta2; D007375:Interleukin-1 / Q000494:pharmacology; D016209:Interleukin-8 / Q000494:pharmacology; D008070:Lipopolysaccharides / Q000008:administration & dosage; D009521:Newcastle Disease / Q000276:immunology*; D009522:Newcastle disease virus / Q000276:immunology*; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D012333:RNA, Messenger / Q000235:genetics; D051381:Rats; D019311:Staurosporine; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
chemical_list: D000470:Alkaloids; D002352:Carrier Proteins; D003176:Complement C3; D003180:Complement C3b Inactivator Proteins; D003181:Complement C4; D016207:Cytokines; D016167:Integrin alphaXbeta2; D007375:Interleukin-1; D016209:Interleukin-8; D008070:Lipopolysaccharides; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; D017242:Complement Factor H; D011493:Protein Kinase C; D019311:Staurosporine